Poor
Poorly Aligned
Patient Risk:
Moderate
Summary
Most claims are not established by the supplied ibuprofen label sections, which do not address SSRIs, SSRI-specific dosing, or most of the cited risk estimates and recommendations. The label does support a higher GI-bleeding risk when warfarin-type anticoagulants are used with NSAIDs and advises caution in patients 65 years and older.
Category Scores
Accurate Statements
The claim that concurrent anticoagulant use raises GI bleeding risk has limited support for warfarin-type anticoagulants used with NSAIDs.
The Drug Interactions section states that warfarin and NSAIDs have synergistic effects on GI bleeding, producing higher risk than either drug alone. It does not address an added SSRI or establish the claim for all anticoagulants.
The claim concerning people over 65 has limited support as a general caution about NSAID use in older adults.
The Geriatric Use section advises caution when treating patients 65 years and older with NSAIDs. It does not specify an SSRI-related GI bleeding risk.
Unsupported Statements
Claims that no ibuprofen dosage adjustment is needed with SSRIs, that ibuprofen and SSRIs are commonly used together without mandatory changes, and that SSRIs do not materially affect ibuprofen absorption, metabolism, or clearance.
The supplied sections do not discuss SSRIs or ibuprofen dose adjustment, absorption, metabolism, or clearance in SSRI users.
Claims that SSRI–ibuprofen use principally raises GI bleeding risk rather than requiring dose adjustment, and that SSRIs inhibit platelet serotonin uptake or impair platelet aggregation.
The supplied sections do not describe SSRI-associated bleeding mechanisms or identify the main concern or dose-management approach for this combination.
Claims that ibuprofen damages the gastric mucosa or generally weakens platelet function.
The supplied sections do not make these claims. They describe ibuprofen interference with aspirin's antiplatelet activity, not a general effect on platelet function or gastric mucosal damage.
Claims of a 2–6-fold increase in upper GI bleeding, an annual absolute risk under 1%, and increased risk from more than 1200 mg daily with an SSRI.
The supplied sections provide none of these estimates or dose thresholds.
Claims that peptic-ulcer history, SSRI type, or SSRI potency—including paroxetine—determines bleeding risk with ibuprofen.
The supplied sections do not discuss peptic-ulcer history or compare SSRIs. The only relevant bleeding-risk statement concerns warfarin-type anticoagulants with NSAIDs.
Recommendations to use the lowest effective dose, use 200–400 mg as needed, substitute acetaminophen, or routinely prescribe a proton pump inhibitor, including recommendations attributed to ACG, NICE, or AGA.
The supplied sections do not provide these dosing or gastroprotection recommendations or cite these organizations.
Recommendations to monitor for black stools, abdominal pain, or anemia, particularly during the first 30 days.
The supplied sections do not provide these monitoring instructions or specify a monitoring period.
Claims about SSRI labeling, guideline advice, randomized-trial or case-control evidence, and the Danish registry estimate.
The supplied ibuprofen label sections do not discuss SSRI labels, these guidelines, the evidence base, or the cited study.
Claims about acetaminophen's interactions or place in therapy, celecoxib's properties and comparative risks, and topical diclofenac's exposure or safety.
The supplied sections do not discuss these drugs or make these comparisons.
Contradictions
Important Omissions
The anticoagulant claim should distinguish the label's specific warning about warfarin-type anticoagulants used with NSAIDs from the unsupported extension to an ibuprofen–SSRI–anticoagulant combination.
Importance:
Moderate
The age-related claim should distinguish the label's general advice to use caution with NSAIDs in patients 65 years and older from an SSRI-specific GI bleeding risk claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The supplied sections do not support most of the specific SSRI-related dosing, bleeding estimates, monitoring instructions, and gastroprotection recommendations. The claims should not be presented as established by this label; the label does support caution with warfarin-type anticoagulants and NSAIDs and general caution in older adults.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Poorly Aligned
Primary Issue
Most claims, including SSRI-specific dosing and bleeding recommendations, are not addressed by the supplied label sections.
Suggested Improvement
Limit label-based statements to the supplied text: warfarin-type anticoagulants used with NSAIDs have synergistic GI-bleeding risk, and caution is advised when treating patients 65 years and older. Clearly identify other SSRI-specific claims and recommendations as not established by these sections.